Thompson V, et al. E ect of azithromycin on systemic markers of inflammation in cystic fibrosis patients uninfected with Pseudomonas aeruginosa. Chest 2012 May 17 [Epub ahead of print].

No abstract

Analysis 3.4. Comparison 3 RMT (40% of maximal e ort) versus control, Outcome 4 Forced vital capacity (% predicted)............ Analysis 3.5. Comparison 3 RMT (40% of maximal e ort) versus control, Outcome 5 Inspiratory muscle endurance (% PImax)..... Analysis 4.1. Comparison 4 RMT (20% of maximal e ort) versus control, Outcome 1 Forced expiratory volume at one second

Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group. Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 11, 2016.

No abstract